Cann restated their hold rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report released on Sunday morning.

“CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018.”,” Cann’s analyst commented.

A number of other research firms have also commented on CRSP. BidaskClub lowered shares of Crispr Therapeutics from a buy rating to a hold rating in a research note on Saturday, December 2nd. Chardan Capital reaffirmed a buy rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. SunTrust Banks reaffirmed a hold rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Barclays reaffirmed a buy rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research note on Friday, September 8th. Finally, Oppenheimer initiated coverage on shares of Crispr Therapeutics in a research note on Thursday, December 7th. They issued a hold rating for the company. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $22.38.

Crispr Therapeutics (NASDAQ CRSP) opened at $18.30 on Friday. Crispr Therapeutics has a 52 week low of $11.63 and a 52 week high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. During the same period in the prior year, the business posted ($2.77) EPS. The company’s revenue for the quarter was up 54.2% on a year-over-year basis. equities research analysts anticipate that Crispr Therapeutics will post -2.46 earnings per share for the current fiscal year.

In other Crispr Therapeutics news, Director Thomas Woiwode sold 1,700 shares of the stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total value of $34,357.00. Following the completion of the sale, the director now owns 8,218 shares in the company, valued at approximately $166,085.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Corp /De/ Celgene sold 87,991 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $19.10, for a total transaction of $1,680,628.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,935,654 shares of company stock valued at $36,843,188. Insiders own 39.98% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CRSP. Granahan Investment Management Inc. MA raised its holdings in shares of Crispr Therapeutics by 51.7% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after purchasing an additional 89,839 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $2,384,000. Adams Street Partners LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $1,019,000. Hershey Trust Co. bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $768,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $536,000. Institutional investors own 24.55% of the company’s stock.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/crispr-therapeutics-crsp-earns-hold-rating-from-cann/1762528.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.